Breaking News
Get 45% Off 0
🌊 NVIDIA ripple effect: Track AI stocks' response to chip giant's earnings
Explore AI Stocks

Here's Why You Should Hold On To Inogen (INGN) Stock For Now

By Zacks Investment ResearchStock MarketsMar 24, 2020 10:03PM ET
www.investing.com/analysis/heres-why-you-should-hold-on-to-inogen-ingn-stock-for-now-200518909
Here's Why You Should Hold On To Inogen (INGN) Stock For Now
By Zacks Investment Research   |  Mar 24, 2020 10:03PM ET
Saved. See Saved Items.
This article has already been saved in your Saved Items
 
 
US500
+0.02%
Add to/Remove from Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
AAPL
-2.70%
Add to/Remove from Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
SYK
+0.37%
Add to/Remove from Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
ARAY
+1.49%
Add to/Remove from Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
COO
+0.81%
Add to/Remove from Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
INGN
-14.81%
Add to/Remove from Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
Inogen, Inc. (NASDAQ:INGN) is likely to gain from a solid product portfolio and a strong revenue guidance. However, the company is currently facing global headwinds.
Shares of the company have lost 44.9% compared with the industry's 20.8% decline in a year’s time. The current level also compares unfavorably with the S&P 500 index’s 30.2% decline over the same time frame.
This $1.07-billion medical technology company currently has a Zacks Rank #3 (Hold). Inogen’s earnings are expected to grow 11.1% in the next five years. However, the company has a trailing four-quarter positive earnings surprise of 7.2%, on average.
Let’s take a closer look at the factors working in favor of the company right now.
Product Portfolio & Guidance
Inogen’s expanding product portfolio is a key catalyst. The company provides oxygen concentrator solutions for portable and stationary use. Inogen’s flagship product, One G4, is a single-solution portable oxygen concentrator. Recently, the company launched the Inogen One G5 in the domestic business-to-business arm. In fact, the company applied for CE marking for the same and has begun shipments to international customers.
Management also confirmed plans of incorporating the Tidal Assist Ventilator directly into the Inogen One Portable Oxygen Concentrators and making the SideKick TAV product compatible with the Inogen At-Home Stationary Concentrator.
Furthermore, despite a recent decline in revenues, Inogen has kept its revenue guidance intact.
For 2020, Inogen continues to expect revenues of $385-$400 million, calling for 6.4-10.5% year-over-year growth, with modest growth in rental revenues for 2020 compared with that in 2019.
Deterrents
Inogen has been facing global headwinds of late. The company’s international business-to-business revenues fell 7.7% year over year and 5.1% at constant currency in recent times, primarily due to tender uncertainty in certain European regions and currency headwinds.
Resultantly, the company now expects to report a loss per share for the first quarter of 2020. Additionally, Inogen expects 2020 EBITDA of $44-$50 million, down from the earlier projected $56-$58 million.
Estimates Picture
For 2020, the Zacks Consensus Estimate for revenues is pegged at $83.35 million. For adjusted earnings per share, the same stands at a loss of 10 cents.
Key Picks
Some better-ranked companies in the broader medical sector include Stryker Corporation (NYSE:SYK) , Accuray Incorporated (NASDAQ:ARAY) and The Cooper Companies (NYSE:COO) , each carrying a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Stryker’s long-term earnings growth is expected at 10.1%.
Accuray’s fiscal fourth-quarter earnings are expected to skyrocket 150%.
Cooper Companies' long-term earnings growth is projected at 10.7%.
More Stock News: This Is Bigger than the iPhone!
It could become the mother of all technological revolutions. Apple (NASDAQ:AAPL) sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 27 billion devices in just 3 years, creating a $1.7 trillion market.
Zacks has just released a Special Report that spotlights this fast-emerging phenomenon and 6 tickers for taking advantage of it. If you don't buy now, you may kick yourself in 2020.


Stryker Corporation (SYK): Free Stock Analysis Report

Accuray Incorporated (ARAY): Free Stock Analysis Report

The Cooper Companies, Inc. (COO): Free Stock Analysis Report

Inogen, Inc (INGN): Free Stock Analysis Report

Original post

Zacks Investment Research
Here's Why You Should Hold On To Inogen (INGN) Stock For Now
 

Related Articles

Here's Why You Should Hold On To Inogen (INGN) Stock For Now

Add a Comment

Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.
  • Any comment you publish, together with your investing.com profile, will be public on investing.com and may be indexed and available through third party search engines, such as Google.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

Write your thoughts here
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Apple
Continue with Google
or
Sign up with Email